TR200201014T2 - Heterosiklik sodyum/proton değişim önleyicileri ve metot - Google Patents

Heterosiklik sodyum/proton değişim önleyicileri ve metot

Info

Publication number
TR200201014T2
TR200201014T2 TR2002/01014T TR200201014T TR200201014T2 TR 200201014 T2 TR200201014 T2 TR 200201014T2 TR 2002/01014 T TR2002/01014 T TR 2002/01014T TR 200201014 T TR200201014 T TR 200201014T TR 200201014 T2 TR200201014 T2 TR 200201014T2
Authority
TR
Turkey
Prior art keywords
proton exchange
heterocyclic
sodium
heteroaryl
exchange inhibitors
Prior art date
Application number
TR2002/01014T
Other languages
English (en)
Inventor
Ahmad Saleem
C.Wu Shung
V.O'neil Steven
Ngu Khehyong
S. Atwal Karnail
S.Weinstein David
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of TR200201014T2 publication Critical patent/TR200201014T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

n'nin 1 ila 5 arasinda oldugu; X'in N ya da C-R5(ki buradaki R5, H, halo, alkenil,alkinil, alkoksi, alkil, aril ya da heteroarildir) oldugu; Z'nin bir heteroaril grubu oldugu; R , R , R ve R4'ün burada tanimlandigi gibi oldugu ve X'in N, R 'in tercihen aril ya da heteroaril oldugu yapi (I)'e sahip sodyum/proton degisim (NHE) önleyicileri olan heterosiklik saglanmistir ve bunlari, antianjinal ve kardiyo koruyucu maddeler olarak faydalidir. Ayrica anjin pektoris, kardiyak fonksiyonsuzluk, miyokardiyal nekroz ve aritmanin önlenmesi ya da tedavi edilmesine yönelik, yukaridaki heterosiklik türevlerin kullanildigi bir metot da saglanmistir.
TR2002/01014T 1999-10-12 2000-10-02 Heterosiklik sodyum/proton değişim önleyicileri ve metot TR200201014T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15875599P 1999-10-12 1999-10-12

Publications (1)

Publication Number Publication Date
TR200201014T2 true TR200201014T2 (tr) 2003-01-21

Family

ID=22569562

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/01014T TR200201014T2 (tr) 1999-10-12 2000-10-02 Heterosiklik sodyum/proton değişim önleyicileri ve metot

Country Status (26)

Country Link
US (2) US6887870B1 (tr)
EP (1) EP1224183B1 (tr)
JP (1) JP2003527331A (tr)
KR (1) KR20020038818A (tr)
CN (1) CN1468232A (tr)
AR (1) AR026023A1 (tr)
AT (1) ATE314364T1 (tr)
AU (1) AU7859600A (tr)
BR (1) BR0014725A (tr)
CA (1) CA2388813A1 (tr)
CO (1) CO5251416A1 (tr)
DE (1) DE60025245T2 (tr)
DK (1) DK1224183T3 (tr)
ES (1) ES2254236T3 (tr)
HK (1) HK1045691A1 (tr)
HU (1) HUP0300195A3 (tr)
IL (1) IL148517A0 (tr)
MX (1) MXPA02003626A (tr)
NO (1) NO20021717L (tr)
NZ (1) NZ517668A (tr)
PE (1) PE20011001A1 (tr)
PL (1) PL366131A1 (tr)
RU (1) RU2002111867A (tr)
TR (1) TR200201014T2 (tr)
WO (1) WO2001027107A2 (tr)
ZA (1) ZA200202479B (tr)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
EP1444981A1 (en) * 2001-10-11 2004-08-11 Katsuhiko Mikoshiba Intracellular calcium concentration increase inhibitors
JP2005513031A (ja) * 2001-11-26 2005-05-12 アラクノーバ・セラピューティックス・リミテッド 肺線維症の処置のためのｐｐａｒアクチベーターの使用
AU2003263393A1 (en) * 2002-09-04 2004-03-29 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
EP1554262B1 (en) 2002-10-23 2007-12-05 Glenmark Pharmaceuticals Limited Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
BR0316306A (pt) 2002-11-18 2005-09-27 Novartis Ag Compostos orgânicos
DK1599468T3 (da) * 2003-01-14 2008-02-04 Arena Pharm Inc 1,2,3-trisubstituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser forbundet dermed såsom diabetes og hyperglykæmi
SI1599468T1 (sl) * 2003-01-14 2008-02-29 Arena Pharm Inc 1,2,3-trisubstituirani arilni in heteroarilni derivati kot modulatorji metabolizma ter profilaksa in zdravljenje motenj v zvezi z njim, kot diabetesain hiperglikemije
NZ542882A (en) 2003-04-11 2007-10-26 Glenmark Pharmaceuticals Sa Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
EP1862181A3 (en) * 2003-04-11 2010-09-15 High Point Pharmaceuticals, LLC New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof
AU2003901812A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphates of secondary alcohols
CN1795181A (zh) * 2003-05-29 2006-06-28 麦克公司 用作11β－羟基类固醇脱氢酶－1抑制剂的三唑衍生物
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
AR045047A1 (es) * 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
MXPA06000554A (es) 2003-07-14 2006-07-03 Arena Pharm Inc Derivados arilo y heteroarilo fusionados como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con los mismos.
KR100954415B1 (ko) 2003-07-24 2010-04-26 유로-셀띠끄 소시에떼 아노님 피페리딘 화합물 및 그들을 포함하는 약학적 조성물
US8455489B2 (en) * 2003-11-10 2013-06-04 Exelixis, Inc. Substituted pyrimidine compositions and methods of use
US8519158B2 (en) * 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
JP2009519206A (ja) 2004-10-13 2009-05-14 グレンマーク・ファーマシューティカルズ・エスエー Ｎ−（３，５−ジクロロピリジン−４−イル）−４−ジフルオロメトキシ−８−メタンスルホンアミド−ジベンゾ［ｂ，ｄ］フラン−１−カルボキサミドの製造法
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
US7943634B2 (en) 2004-12-17 2011-05-17 Glenmark Pharmaceuticals S.A. Substituted benzo[4,5]furo[3,2-c]pyridine derivatives as PDE 4 inhibitors
WO2006064355A2 (en) 2004-12-17 2006-06-22 Glenmark Pharmaceuticals S.A. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
US7807691B2 (en) 2005-05-13 2010-10-05 Eli Lilly And Company Substituted N-arylpyrrolidines as selective androgen receptor modulators
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
ES2571533T3 (es) 2007-04-27 2016-05-25 Purdue Pharma Lp Antagonistas de TRPV1 y usos de los mismos
WO2008133973A1 (en) 2007-04-27 2008-11-06 Purdue Pharma L.P. Therapeutic agents useful for treating pain
BRPI0812590A2 (pt) 2007-06-05 2015-02-18 Sanofi Aventis Derivados de di(hetero) aricicloexano, sua preparação, seu uso e composições farmacêuticas compreendendo-os
GB0818241D0 (en) * 2008-10-06 2008-11-12 Cancer Res Technology Compounds and their use
US8703962B2 (en) * 2008-10-24 2014-04-22 Purdue Pharma L.P. Monocyclic compounds and their use as TRPV1 ligands
US8759362B2 (en) * 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
PT2384318T (pt) 2008-12-31 2018-02-07 Ardelyx Inc Compostos e métodos para inibir o antiporte mediado por nhe no tratamento de distúrbios associados com a retenção de fluidos ou sobrecarga de sal e distúrbios do trato gastrointestinal
WO2011162409A1 (en) 2010-06-22 2011-12-29 Shionogi & Co., Ltd. Compounds having trpv1 antagonistic activity and uses thereof
CN103221410B (zh) 2010-09-22 2017-09-15 艾尼纳制药公司 Gpr119受体调节剂和对与其相关的障碍的治疗
GB201105659D0 (en) 2011-04-01 2011-05-18 Xention Ltd Compounds
CN103814016B (zh) * 2011-06-10 2017-03-08 默克专利有限公司 生产具有btk抑制活性的嘧啶和吡啶化合物的组合物和方法
TWI453205B (zh) 2011-06-22 2014-09-21 Purdue Pharma Lp 包含二羥基取代基之ｔｒｐｖ１拮抗劑及其用途
US9394293B2 (en) 2011-08-10 2016-07-19 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
AR090037A1 (es) 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
US8765959B2 (en) * 2011-12-23 2014-07-01 Boehringer Ingelheim International Gmbh Piperidine derivatives
AR090880A1 (es) * 2012-04-30 2014-12-10 Janssen R & D Ireland Derivados de pirimidina
BR112014026828A2 (pt) * 2012-05-30 2017-06-27 Hoffmann La Roche compostos de triazolo como inibidores de pde10
WO2014010748A1 (en) * 2012-07-10 2014-01-16 Shionogi & Co., Ltd. Cyclopropane derivative having bace1 inhibiting activity
JP6009851B2 (ja) * 2012-07-27 2016-10-19 日本曹達株式会社 １ｈ−テトラゾール誘導体の製造方法
MX366293B (es) 2012-08-21 2019-07-04 Ardelyx Inc Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
JP6377132B2 (ja) 2013-04-12 2018-08-22 アーデリクス，インコーポレーテッド Ｎｈｅ３結合化合物およびリン酸輸送の阻害方法
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
SI3310760T1 (sl) 2015-06-22 2023-02-28 Arena Pharmaceuticals, Inc. Kristalinična L-argininska sol (R)-2-(7-(4-ciklopentil-3-(trifluorometil)benziloksi)-1,2,3,4- tetrahidrociklo-penta(b)indol-3-il)ocetne kisline za uporabo pri motnjah, povezanih z receptorjem S1P1
CN109153649B (zh) 2016-03-22 2022-04-19 默沙东公司 烟碱乙酰胆碱受体的变构调节剂
KR102456521B1 (ko) 2016-04-29 2022-10-20 아이오메트 파마 엘티디 인돌아민 2,3-디옥시게나제 및/또는 트립토판-2,3-디옥시게나제의 억제제로서의 신규 치환된 이미다조피리딘 화합물
UA126283C2 (uk) 2017-01-09 2022-09-14 Арделікс, Інк. Сполуки, придатні для лікування розладів шлунково-кишкового тракту
US11147884B2 (en) 2017-01-09 2021-10-19 Ardelyx, Inc. Inhibitors of NHE-mediated antiport
EP3582772A1 (en) 2017-02-16 2019-12-25 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
WO2018149940A1 (en) 2017-02-17 2018-08-23 Quimica Sintetica, S. A. Process for the preparation of enantiomerically enriched dihydrobenzofurans and intermediate compounds obtained in the process
WO2018224455A1 (en) 2017-06-07 2018-12-13 Basf Se Substituted cyclopropyl derivatives
WO2018234488A1 (en) 2017-06-23 2018-12-27 Basf Se SUBSTITUTED CYCLOPROPYL DERIVATIVES
MX2020001412A (es) 2017-08-04 2020-08-03 Ardelyx Inc Compuestos y métodos para tratar la hiperpotasemia.
WO2019121143A1 (en) 2017-12-20 2019-06-27 Basf Se Substituted cyclopropyl derivatives
EP3921327B1 (en) 2019-02-07 2023-04-05 Ardelyx, Inc. Glycyrrhetinic acid derivatives for use in treating hyperkalemia
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス， インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ
FI4031547T3 (fi) 2019-09-18 2024-09-16 Takeda Pharmaceuticals Co Plasman kallikreiinin estäjiä ja niiden käyttötapoja
JP2022549601A (ja) 2019-09-18 2022-11-28 武田薬品工業株式会社 ヘテロアリール血漿カリクレインインヒビター
WO2022086920A1 (en) * 2020-10-20 2022-04-28 Blacksmith Medicines, Inc. Glutaminyl-peptide cyclotransferase like (qpctl) protein inhibitors and uses thereof
EP4308228A1 (en) * 2021-03-17 2024-01-24 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206498B (it) 1983-07-18 1989-04-27 Angeli Inst Spa Derivati amidinici del4-fenilmidazolo 2-sostituto processi per la loro preparazione e loro uso farmaceutico.
FR2579596B1 (fr) * 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
IT1201454B (it) * 1985-08-19 1989-02-02 Boehringer Biochemia Srl 1,4-diidropiridine-2-sostituite
US4663473A (en) * 1986-08-25 1987-05-05 The United States Of America As Represented By The Secretary Of The Army Isocyanates from oxalyl chloride and amines
FR2674855B1 (fr) * 1991-04-03 1994-01-14 Synthelabo Derives de piperidine, leur preparation et leur application en therapeutique.
US5380858A (en) * 1992-04-01 1995-01-10 The University Of Toledo Process for the preparation of intermediates useful for the synthesis of histamine receptor antagonists
FR2696177B1 (fr) * 1992-09-28 1995-05-12 Synthelabo Dérivés de pipéridine, leur préparation et leur application en thérapeutique.
MY117098A (en) * 1996-01-15 2004-05-31 Janssen Pharmaceutica Nv Angiogenesis inhibiting pyridazinamines
FR2765221B1 (fr) 1997-06-25 1999-07-30 Synthelabo Derives de 4-[(1h-imidazol-4-yl)piperidin-1-yl]anilide, leur preparation et leur application en therapeutique
FR2765580B1 (fr) 1997-07-01 1999-08-06 Synthelabo Derives de (1h-imidazol-4-yl)piperidine, leur preparation et leur application en therapeutique
FR2772377B1 (fr) * 1997-12-12 2000-01-07 Synthelabo Derives de 1-(1-h-imidazol-2-yl)pyrrolidines et 1-(1-h-imidazol-2-ylpiperidines), leur preparation et leur application en therapeutique
US6011059A (en) * 1997-12-24 2000-01-04 Bristol-Myers Squibb Company Acyl guanidine sodium/proton exchange inhibitors and method
EP1136489A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-[Piperidin-1-yl]pyrimidone derivatives

Also Published As

Publication number Publication date
AU7859600A (en) 2001-04-23
DE60025245T2 (de) 2006-08-24
DK1224183T3 (da) 2006-03-06
US20050137216A1 (en) 2005-06-23
PL366131A1 (en) 2005-01-24
IL148517A0 (en) 2002-09-12
JP2003527331A (ja) 2003-09-16
EP1224183A2 (en) 2002-07-24
BR0014725A (pt) 2003-06-17
WO2001027107A3 (en) 2002-01-24
MXPA02003626A (es) 2003-09-22
ZA200202479B (en) 2004-10-27
HK1045691A1 (zh) 2002-12-06
NO20021717D0 (no) 2002-04-11
NO20021717L (no) 2002-06-10
CN1468232A (zh) 2004-01-14
KR20020038818A (ko) 2002-05-23
DE60025245D1 (de) 2006-02-02
NZ517668A (en) 2004-09-24
WO2001027107A2 (en) 2001-04-19
US7326705B2 (en) 2008-02-05
ATE314364T1 (de) 2006-01-15
AR026023A1 (es) 2002-12-26
CO5251416A1 (es) 2003-02-28
HUP0300195A3 (en) 2003-09-29
EP1224183B1 (en) 2005-12-28
HUP0300195A2 (hu) 2003-07-28
CA2388813A1 (en) 2001-04-19
RU2002111867A (ru) 2004-05-10
PE20011001A1 (es) 2001-11-25
US6887870B1 (en) 2005-05-03
ES2254236T3 (es) 2006-06-16

Similar Documents

Publication Publication Date Title
TR200201014T2 (tr) Heterosiklik sodyum/proton değişim önleyicileri ve metot
YU43001A (sh) Supstituisani biciklični derivati korisni kao sredstva protiv kancera
AU2019502A (en) Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto
PT1162980E (pt) Tratamento de patologias cardiovasculares e patologias relacionadas
WO2003050261A3 (en) (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase
MXPA02003977A (es) Inhibidores de adhesion de celula mediada por al°2.
ATE389635T1 (de) Pharmazeutisch wirksame piperidinderivate
TW200700393A (en) Novel cis-2,4,5-triaryl-imidazolines
BR0114045A (pt) Poliarilcarboxamidas úteis como agentes redutores de lipìdeos
AP1902A (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials
ATE241621T1 (de) Arylsulfonyle als faktor xa inhibitoren
EA200200374A1 (ru) Производные хинолилпропилпиперидина, их получение и содержащие их композиции
MXPA04001037A (es) Derivados de n-fenilpirrol guanidina como ligandos del receptor de melanocortina.
ATE309237T1 (de) Aromatische heterozyklische verbindungen als antientzündungwirkstoffe
DK1040108T3 (da) Orthoanthranilamidderivater som antikoagulanter
PT1007523E (pt) Derivados indole e 2,3-di-ridroindole, sua preparacao e utilizacao
ATE290382T1 (de) Heterozyklische kalium-kanal inhibitoren
NO20020938D0 (no) Substituerte alfa-hydroksysyre-caspaseinhibitorer og deres anvendelse
TR200403436T2 (tr) Kristalin 1-metilkarbapenem türevleri.
NO984740L (no) Isatinderivater som acetylcholinesteraseinhibitorer og analgetiske midler
AU2492500A (en) Aspartic protease inhibitors, compositions, and associated therapeutic methods
BR0014990A (pt) Derivados de tetrahidrotiopirano ranftalazinona como inibidores de pde4
IL136359A (en) Dihydrobenzofuran substituted phthalazin-1-one derivatives and pharmaceutical compositions containing the same
YU30603A (sh) Derivati premošćenog piperazina
ATE276259T1 (de) Dihydroporphyrinderivate und ihre verwendung